Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody^® Molecules ¹⁷⁷Lu-ABY-271 and ¹⁷⁷Lu-ABY-027: Impact of DOTA Position on ABD Domain

• Main Authors: Yongsheng Liu (Author), Anzhelika Vorobyeva (Author), Tianqi Xu (Author), Anna Orlova (Author), Annika Loftenius (Author), Theresa Bengtsson (Author), Per Jonasson (Author), Vladimir Tolmachev (Author), Fredrik Y. Frejd (Author)
• Format: Book
• Published: MDPI AG, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Radiolabeled Affibody-based targeting agent ¹⁷⁷Lu-ABY-027, a fusion of an anti-HER2 Affibody molecule with albumin binding domain (ABD) site-specifically labeled at the C-terminus, has demonstrated a promising biodistribution profile in mice; binding of the construct to albumi...